|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.73 CAD | +0.70% |
|
+0.17% | +10.40% |
| Mar. 22 | Knight Therapeutics Price Target Raised to $7 at RBC | MT |
| Mar. 21 | Knight Therapeutics Reports Fourth Quarter Results | MT |
Knight Therapeutics Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was CAD 74.2 million compared to CAD 81.66 million a year ago. Net loss was CAD 24.33 million compared to CAD 15.19 million a year ago.
Basic loss per share from continuing operations was CAD 0.23 compared to CAD 0.13 a year ago. Diluted loss per share from continuing operations was CAD 0.23 compared to CAD 0.13 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +10.40% | 424M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
KNIGHT THERAPEUTICS INC. 
